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The Clinical Trial Design and Development Working Group within the Quantitative Imaging Network
focuses on providing support for the development, validation, and harmonization of quantitative imag-
ing (QI) methods and tools for use in cancer clinical trials. In the past 10 years, the Group has been
working in several areas to identify challenges and opportunities in clinical trials involving QI and radi-
ation oncology. The Group has been working with Quantitative Imaging Network members and the
Quantitative Imaging Biomarkers Alliance leadership to develop guidelines for standardizing the
reporting of quantitative imaging. As a validation platform, the Group led a multireader study to test a
semi-automated positron emission tomography quantification software. Clinical translation of QI tools
cannot be possible without a continuing dialogue with clinical users. This article also highlights the out-
reach activities extended to cooperative groups and other organizations that promote the use of QI
tools to support clinical decisions.
INTRODUCTION
The Quantitative Imaging Network (QIN) program under the
National Cancer Institute (NCI) is chartered to improve clinical deci-
sion-making by developing and validating quantitative imaging
(QI) methods including data acquisition and analysis methods to
support the measure and prediction of tumor response to therapy
(1). The clinical focus of the QIN requires both the promotion and
the broad dissemination of the aforementioned tools within the
imaging and clinical oncology communities (2). To accomplish
these goals, the QIN brought together multidisciplinary teams
under the governance of the Executive Committee comprising QIN
principal investigators and the Coordinating Committee with lead-
ers from three working groups (WGs) (Figure 1). These WGs are
tasked with addressing problems encountered in Clinical Trial
Design and Development (CTDD), Bioinformatics and Data Sharing
(BIDS), and Image Analysis and Performance Metrics (IAPM), with
subgroups focusing on positron emission tomography computed
tomography (PET-CT) and magnetic resonance imaging (MRI). In
this article, we summarize the activities and challenges of the
CTDD working group (CTDDWG) in the past 10 years.
The mission of the CTDDWG is to develop, validate, and har-
monize methods and tools of quantitative imaging for use in
cancer clinical trials to predict outcome and tumor response to
therapy. This group specifically aims to:
1. Identify challenges and opportunities in CTDD relevant to
trials using QI.
2. Identify best practices for QI-based clinical trial design,
analysis, and reporting.
3. Facilitate and introduce QIN-developed methods into cancer
imaging trials through collaboration with other QINWGs.
4. Disseminate the best clinical trial design and development
method through publications and guidelines.
5. Facilitate outreach to cooperative groups and organiza-
tions to apply QIN methods in multicenter trials through
cross-membership, education, and presentations.
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6. Translate relevant and mature QIN methods into clinical
practice settings as appropriate.
Initial activities of the CTDDWG began in 2008 that involved
a fledgling group of 5 institutions. Initial efforts sought to iden-
tify constraints of using QI in oncology trials that included a
review published by Kurland et al. (3) to examine the potential
constraints on clinical trials involving QI and strategies to over-
come them. The group additionally explored barriers to effec-
tively accrue patients to single- and multi-institutional trials.
The CTDDWG was active in presenting at national meetings
such as American Society for Therapeutic Radiology and Oncology
(ASTRO), American Association of Cancer Research (AACR), and
the Radiological Society of North America (RSNA) to publicize the
work of the QIN and the potential for these tools to impact clinical
trials. A white paper was published in Clinical Cancer Research (4),
and a letter to Cancer Center Directors was published in the Journal
of Clinical Oncology (5).
IDENTIFY CHALLENGES AND OPPORTUNITIES IN
CLINICAL TRIAL DESIGN AND DEVELOPMENT
Patient accrual is essential for the success of clinical trials. With
additional procedures and administration of imaging agents, tri-
als involving the development of new QI methods/tools may face
more challenges in patient recruitment. The CTDDWG surveyed
25 prospective clinical studies from 12 sites to evaluate the
accrual performance, barriers, and solutions that are specific to
QI-based trials (6). Our findings showed that the median percent
annual accrual attained was 94.5% (range, 3%–350%). The most
common barrier to recruitment was that “patients decline partici-
pation” (44%), followed by “too few eligible patients” (40%).
Response from our survey indicated that interactions between
institutions, physicians, and patients are essential factors for
accrual success, with attention paid to ensuring and communi-
cating potential trial benefits to enrolled and future patients.
Recent advances in radiation oncology have shown an
increasing reliance on both high-resolution anatomic-based
imaging (CT and MRI) and functional imaging (PET, diffusion-
weighted imaging (DWI), magnetic resonance spectroscopic
(MRS) imaging, etc.) for accurate radiation therapy delivery. The
CTDDWG reviewed the utility of QI by CT, MRI, and PET/single-
photon emission computed tomography (SPECT) with different
tracers for radiation treatment planning and patient management
(7). It was concluded that QI provides quantitative measures that
complement the standard qualitative assessment methods.
Further integration of QI into the radiation oncology workflow
for treatment planning, risk stratification, guidance of dose esca-
lation, and characterization of post-treatment effects is expected.
IDENTIFY BEST PRACTICES FOR CLINICAL TRIAL
DESIGN, ANALYSIS, AND REPORTING
As QI methods are being increasingly used in clinical trials as pri-
mary, secondary, or correlative endpoints, standard criteria for
QI reporting should be defined to ensure that quantitative data
extracted from images are reported in a meaningful, consistent,
Figure 1. Quantitative Imaging Network (QIN)
governance structure. The Executive Committee
oversees the entire technical network, while the
Coordinating Committee deals with working group
(WG) issues. Each QIN technical team provides
membership to all of theWGs, namely, Clinical
Trial Design and Development and Data
Acquisition, Bioinformatics and Data Sharing, and
Image Analysis and PerformanceMetrics, with sub-
groups focusing on positron emission tomography-
computed tomography (PET-CT) and magnetic
resonance imaging (MRI).
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and repeatable manner. The group led the effort of assembling a
guideline of what is viewed as “best practices” for reporting (and
potentially assessing) studies in which QI has been performed
and reported. This guideline of standardizing the reporting of
quantitative imaging (STIRQI) adapts the STAndards for
Reporting of Diagnostic Accuracy (STARD) criteria first
reported in 2003 (8, 9) and subsequently updated in 2015 (10–
12). Information regarding the purpose/background of the
study, patient characteristics, image acquisition methodology,
quantification methods, and statistical analysis should be
described in detail. The outcome of the STIRQI is to ensure
rigorous approaches are applied in QI studies so that results
are reproducible and suitable for generalization to larger pop-
ulations. Recommendation gathered from members of the
CTDDWG and the leadership of the Quantitative Imaging
Biomarkers Alliance (QIBA) group was drafted in the form of a
white paper that will soon be published.
TRANSLATE RELEVANT AND MATURE QIN
METHODS INTO CLINICAL PRACTICE SETTINGS
PET Response Criteria in Solid Tumors (PERCIST) was initially
proposed by Wahl et al. (13) as an approach to standardize inter-
pretation of FDG-PET results using a consistent PET protocol.
This group examined the variability for interpretation of FDG-
PET results in 22 readers across 15 institutions on 30 test cases
with scans before and after therapy using each institution’s pre-
ferred software for this analysis. This study (14) showed a high
correlation across readers and institutions but also identified
some level of variability. Based on the PERCIST criteria, Wahl’s
team developed a semiautomated QI quantification software
(AutoPERCISTTM) to identify/measure reference tissue (liver), to
set disease threshold values, and to calculate SUVs (standardized
uptake values) (peak, max, mean, volume, and total lesion gly-
colysis). Using the CTDDWG as a testbed for tool validation, a
multireader study was initiated. The main goal was to determine
whether variance among readers and institutions was further
reduced when AutoPERCISTTM was used. The latest version of
this software was installed by 11 participating institutions (from
United States, Asia, and Europe) through a material transfer
agreement (MTA), and the 30 paired cases of anonymized FDG
PET-CT images were downloaded for evaluation. Instructions for
this study were given to each participating institution, with up to
5 tumor lesions from each PET image to be evaluated. All selec-
tions were recorded and sent to the central database of the Image
Response Assessment Team at Johns Hopkins for quality control.
Initial results show that consistent SUVpeak values were obtained,
and the AutoPERCISTTM analysis had less variability than was
seen when different institutional software was used. The initial
results were presented at the Society of Nuclear Medicine and
Molecular Imaging annual meeting (15), and a full manuscript
was drafted and will soon be submitted for publication.
OUTREACH TO COOPERATIVE GROUPS AND
ORGANIZATIONS
The CTDDWG plays a key role in QIN outreach activities with the
goal to raise awareness of the potential utility of advanced quan-
titative imaging for both research and general clinical practice.
Several barriers (shown below) have limited the wider adoption
of advanced quantitative imaging techniques in the clinic. The
CTDDWG designed various panel discussions with oncology
groups to educate trialists about the value of quantitative imag-
ing and further promote the development and validation of new
tools and methods needed to bring quantitative imaging into the
clinical setting.
LearningObjectives
1. Differentiate conventional qualitative from advanced
quantitative imaging techniques and describe the
added value of the quantitative methodologies to clini-
cal management.
2. Demonstrate knowledge of specific tools being developed
by featured QIN research groups that will allow various
advanced quantitative imaging techniques to be utilized
on oncology clinical trials.
3. Demonstrate an understanding of computing architecture/
pipeline and informatic needs to fully exploit development
of quantitative imaging methods/tools for clinical use.
Members from the CTDDWG took the lead to promote the
collaborations with the National Clinical Trials Network (NCTN)
cooperative groups, testing QI tools in the clinical trial settings
in the Alliance, Children’s Oncology Group (COG), Eastern
Cooperative Oncology Group, and the American College of
Radiology Imaging Network (ECOG-ACRIN), NRG Oncology, and
Southwest Oncology Group (SWOG). In addition, special panels
highlighting QIN tools and their potential use in clinical trials
were organized and presented at the American Association for
Physicists in Medicine (AAPM) and the American Society for
Therapeutic Radiology and Oncology (ASTRO) annual meetings.
PATHWAYS FOR QUANTITATIVE IMAGING TOOLS
TO CLINICAL TRANSLATION
Bringing imaging tools and methods into clinical utility is not a
simple task. Tools need be tested–retested, optimized, and vali-
dated to be clinically ready. In addition, open dialogues between
tool developers and clinicians are needed to crystalize tool capa-
bilities that should not only reliably serve specific clinical needs
but also be easily incorporated into the clinical workflow and be
compatible with existing data systems.
To date, there are 67 QIN imaging tools at various stages of
development. Using a benchmark process for clinical-readiness:
1) prebenchmark; 2) basic benchmark; 3) technical test; 4) clini-
cal trial and 5) clinical use, Farahani et al. identified approxi-
mately 12 tools to be qualified at levels 4 and 5 (16). These tools
include software packages for tumor segmentation, volumetric
measurement, metric calculation, and bioinformatics interface
that are all important for disease assessment, management, and
intervention. A representative of QIN tools being used in clinical
trials is listed in Table 1.
To translate these sophisticated tools to the clinic, the QIN
formed a team of “ambassadors,” with members from the
CTDDWG reaching out to the NCTN cooperative groups to high-
light the use of QI tools in treatment trials. In particular, a new
membership was extended to ECOG-ACRIN with the intent of
developing additional resources to support retrospective studies
QIN–CTDDWorking Group
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for tool testing and prospective studies for tool validations.
Through the collaboration between the QIN members and the
National Institute of Standards and Technology (NIST), imaging
phantoms have been developed and commercialized to support
image quality assurance and control (QA/QC) in clinical trials. All
these collaborations and outreach activities have proven to be val-
uable as part of our effort in translating QI to clinical utility.
FUTURE DIRECTIONS
Looking forward, the CTDDWG members are working together to
develop a clear roadmap and imaging workshops to provide
education on how to include QI as part of the clinical trial. Other
future directions also include a new collaboration with the
Bioinformatics and Data Sharing Working Group (BIDSWG) to
package QIN tools into open-source Docker containers (https://
www.docker.com/get-started) in an automated pipeline infra-
structure (17) to facilitate the connection, execution, and deploy-
ment of QIN tools into the clinical workflow. The BIDSWG is
planning to work with the Imaging and Radiation Oncology Core
(IROC) to test and validate the resulting pipeline. Through these
activities, the CTDDWG will continue to facilitate the clinical
translation of QI tools.
ACKNOWLEDGMENT
This work was supported in part by NIH/NCI U01CA151235 and U01CA225427 for
EFJ; U01CA140206 for JMB; U01CA172027 for HKS; U01CA140204 for RLW;
U01CA148131 and U01CA140230 for BFK; U01CA148131 for HML;
U01CA142555, 1U01CA190214, 1U01CA187947, and U01CA242879 for DLR;
U01CA179106 and U01CA232931 for LH; P30CA006973 for MH; and
U01CA140207 for LHS.
REFERENCES
1. Yankeelov TE. The quantitative imaging network: a decade of achievement.
Tomography. 2019;5:A8.
2. Clarke LP, Nordstrom RJ, Zhang H, Tandon P, Zhang Y, RedmondG, Farahani K,
Kelloff G, Henderson L, Shankar L, Deye J, Capala J, Jacobs P. The quantitative imaging
network: NCI’s historical perspective and planned goals. Transl Oncol. 2014;7:1–4.
3. Kurland BF, Gerstner E, Mountz JM, Schwartz LH, Ryan CW, GrahamMM, Buatti JM,
Fennessy FM, Eikman EA, Kumar V, Forster KM,Wahl RL, Lieberman FS. Promise and
pitfalls of quantitative imaging in oncology clinical trials. Magn Reson Imaging.
2012;30:1301–1312.
4. Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM,
Erickson BJ, Fennessy FM, HuangW, Kalpathy-Cramer J, Wahl RL, Linden HM,
Kinahan PE, Zhao B, Hylton NM, Gillies RJ, Clarke L, Nordstrom R, Rubin DL.
Quantitative imaging in cancer clinical trials. Clin Cancer Res.
2016;22:284290.
5. Mountz JM, Yankeelov TE, Rubin DL, Buatti JM, Erikson BJ, Fennessy FM, Gillies RJ,
HuangW, Jacobs MA, Kinahan PE, Laymon CM, Linden HM, Mankoff DA, Schwartz
LH, Shim H,Wahl RL. Letter to cancer center directors: progress in quantitative imag-
ing as a means to predict and/or measure tumor response in cancer therapy trials. J
Clin Oncol. 2014;32:2115–2116.
6. Kurland BF, Aggarwal S, Yankeelov TE, Gerstner ER, Mountz JM, Linden HM, Jones
EF, Bodeker KL, Buatti JM. Accrual patterns for clinical studies involving quantitative
imaging: results of an NCI Quantitative Imaging Network (QIN) survey. Tomography.
2016;2:276–282.
7. Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones EF, Hylton NM,
Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA,
Holdhoff M, Taylor E, Jaffray DA, Schwartz LH, Mankoff DA, Kinahan PE, Linden HM,
Lambin P, Dilling TJ, Rubin DL, Hadjiiski L, Buatti JM. The use of quantitative imaging
in radiation oncology: a Quantitative Imaging Network (QIN) perspective. Int J
Radiat Oncol Biol Phys. 2018;102:1219–1235.
8. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG,
Moher D, Rennie D, de Vet HC; Standards for Reporting of Diagnostic Accuracy.
Towards complete and accurate reporting of studies of diagnostic accuracy: the
STARD initiative. Radiology. 2003;226:24–28.
9. Bossuyt PM, Reitsma JB; Standards for Reporting of Diagnostic Accuracy. The STARD
initiative. Lancet. 2003;361:71.
10. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG,
Moher D, Rennie D, de Vet HCW, Kressel HY, Rifai N, Golub RM, Altman DG,
Hooft L, Korevaar DA, Cohen JF; STARD Group. STARD 2015: an updated list of
essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:
h5527.
11. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG,
Moher D, Rennie D, de Vet HCW, Kressel HY, Rifai N, Golub RM, Altman DG,
Hooft L, Korevaar DA, Cohen JF; STARD Group. STARD 2015: an updated list of
Table 1. Representation of QIN Tools Used in Clinical Trials E
Trial Description Modality Measurement QIN Tool Application
NCT01015833 Phase III randomized study of sor-
afenib þ doxorubicin vs sorafe-







NCT03137888 Spectroscopic MRI-guided radia-




Web-based clinical interface for
spectral MRI analysis, visual-




NCT01042379 I-SPY 2 TRIAL: Neoadjuvant and
personalized adaptive novel
agents to treat breast cancer
MRI Functional tumor
volume
Tool kit for image processing, tis-




NCT02398733 [18F]Fluoroestradiol (FES) PET
as a predictive measure for
endocrine therapy in patients




Phantom and companion soft-







TOMOGRAPHY.ORG I VOLUME 6 NUMBER 2 I JUNE 2020 63
essential items for reporting diagnostic accuracy studies. Radiology. 2015;277:
826–832.
12. Korevaar DA,Wang J, van EnstWA, Leeflang MM, Hooft L, Smidt N, Bossuyt PM.
Reporting diagnostic accuracy studies: some improvements after 10 years of STARD.
Radiology. 2015;274:781–789.
13. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving
considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:
122S–150S.
14. LodgeMA, Holdhoff M, Leal JP, Bag AK, Nabors LB, Mintz A, Lesser GJ, Mankoff DA,
Desai AS, Mountz JM, Lieberman FS, Fisher JD, Desideri S, Ye X, Grossman SA, Schiff
D,Wahl RL. Repeatability of (18)F-FLT PET in a multicenter study of patients with high-
grade glioma. J Nucl Med. 2017;58:393–398.
15. O JH, Leal J,Wahl R. Quantitation of tumor SUL peak on 18F-FDG PET/CT: multicen-
ter assessment using Auto-PERCIST. J Nucl Med. 2018;59:294.
16. Farahani K, Tata D, Nordstrom RJ. QIN benchmarks for clinical translation of quantita-
tive imaging tools. Tomography. 2019;5:1–6.
17. John S, Rubin D, Gude D, Echegaray S, Bakr S, Mattonen S, Napel S. QIFP: a web
application supporting quantitative medical imaging pipelines 2018 [cited 2020
January 09]. Available from: https://cdn.ymaws.com/siim.org/resource/resmgr/
mimi18/abstracts/18paper4-John.pdf
QIN–CTDDWorking Group
64 TOMOGRAPHY.ORG I VOLUME 6 NUMBER 2 I JUNE 2020
